🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 71 of 116

  1. Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  2. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  3. Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  4. Sintilimab (approved)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  5. Sintilimab Combined with Platinum-containing Chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Sintilimab in combination with Multimodality Radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  7. Sintilimab injection plus Inlyta treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

  8. Sintilimab with Interleukin-2+CAPOX

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  9. Sintilimab,nab-paclitaxel and tegio

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  10. Sitravatinib

    BeiGene

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  11. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  12. Sm-EDTMP

    Jazz Pharmaceuticals Ireland Limited

    Metastatic Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  13. Sodium Cridanimod

    Xenetic Biosciences

    Endometrial Cancer

    phase 2 small molecule terminated

    1 trial

  14. SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN

    Pari Pharma GmbH

    recurrent primary supratentorial malignant brain tumors in children

    phase 2 small molecule active

    1 trial

  15. Sorafenib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  16. Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

    Bayer HealthCare AG

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  17. Steroids switch

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  18. Stivarga 40 mg film-coated tablets

    Ningbo Cancer Hospital

    Bone sarcoma

    phase 2 small molecule active

    1 trial

  19. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  20. Streptococcus salivarius K12

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  21. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  22. Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

    Talion

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  23. Sunvozertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  25. Surufatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  26. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  27. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  28. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  29. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  30. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  31. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  33. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  34. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  35. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  36. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  37. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  38. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  39. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  40. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  41. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  42. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  43. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  44. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  45. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  46. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  47. TAK-981

    Takeda

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  48. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.